title: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
abstract: Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this first of 5 sections of the guidelines of care for psoriasis, we discuss the classification of psoriasis; associated comorbidities including autoimmune diseases, cardiovascular risk, psychiatric/psychologic issues, and cancer risk; along with assessment tools for skin disease and quality-of-life issues. Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis.
authors.affiliation: Baylor University Medical Center, Dallas, Texas, USA.
authors.forename: Alan
authors.initials: A
authors.lastname: Menter
authors.forename: Alice
authors.initials: A
authors.lastname: Gottlieb
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Abby S
authors.initials: AS
authors.lastname: Van Voorhees
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Gordon
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
authors.forename: John Y M
authors.initials: JY
authors.lastname: Koo
authors.forename: Craig A
authors.initials: CA
authors.lastname: Elmets
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
authors.forename: Karl R
authors.initials: KR
authors.lastname: Beutner
authors.forename: Reva
authors.initials: R
authors.lastname: Bhushan
mesh_terms: D017255:Acitretin / Q000009:adverse effects; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use; D003863:Depression / Q000209:etiology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D018664:Interleukin-12 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D008223:Lymphoma / Q000209:etiology; D024821:Metabolic Syndrome / Q000150:complications; D008727:Methotrexate / Q000009:adverse effects; D009765:Obesity / Q000150:complications; D011701:PUVA Therapy; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012907:Smoking / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007074:Immunoglobulin G; D053759:Interleukin-23; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D016572:Cyclosporine; D000077944:Alefacept; D017255:Acitretin; D000068800:Etanercept; C472181:efalizumab; D008727:Methotrexate